TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00487695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: confocal laser endomicroscopy (CLE)
Description: Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: confocal laser endomicroscopy (CLE)
Description: Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard endoscopy (EGD)
Description: Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard endoscopy (EGD)
Description: Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
Study: NCT01876745

Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
Study: NCT01120691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237
Description: NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol/albuterol
Description: As needed throughout the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: As needed throughout the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol/albuterol
Description: As needed throughout the study
Study: NCT02571933

Intervention type: OTHER
Intervention: Pre-treatment Faces Pain Scale - Revised
Description: Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.

Intervention type: OTHER
Intervention: Pre-treatment Faces Pain Scale - Revised
Description: Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.

Intervention type: OTHER
Intervention: Pre-treatment Faces Pain Scale - Revised
Description: Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.

Intervention type: OTHER
Intervention: Post-treatment Faces Pain Scale - Revised
Description: Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.

Intervention type: OTHER
Intervention: Post-treatment Faces Pain Scale - Revised
Description: Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.

Intervention type: OTHER
Intervention: Post-treatment Faces Pain Scale - Revised
Description: Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.

Intervention type: OTHER
Intervention: Cognitive interview
Description: Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.

Intervention type: OTHER
Intervention: Cognitive interview
Description: Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.

Intervention type: OTHER
Intervention: Cognitive interview
Description: Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
Study: NCT02889393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Daily 0.05 mg/kg Teduglutide administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Daily 0.05 mg/kg Teduglutide administered subcutaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.
Study: NCT00697918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-333369
Description: 100 mg to 400 mg twice daily
Study: NCT03220256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
Study: NCT04147169

Intervention type: BEHAVIORAL
Intervention: Focused end-of-life conversations to promote connections among patients, family members and clinicians.
Description: All eligible patients and families who were invited to participate in wish elicitation and implementation. For family interviews, criterion sampling was used. For the clinician focus groups, criterion sampling was used, based on involvement in the care of a 3WP patient. For the manager/hospital administrator interviews, purposive sampling was used, based on relevant leadership positions. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data include characteristics of patients, families and clinicians, questionnaire responses from families who agree to interviews, and clinicians who agree to focus groups, respectively, types of wishes elicited and implemented, and their cost. Qualitative data was obtained through individual family interviews, inter-professional clinician focus groups, project team field notes, additional ideas about the costs and benefits of the project from manager interviews, and analysis of project documents.
Study: NCT01558258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness practices (MAPs)
Description: Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
Study: NCT03818074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Wavewriter 1000Hz Spinal cord Stimulation
Description: High frequency spinal cord stimulation.
Study: NCT03442972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03878602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Description: Umbilical cord will be clamped after 1 min after the birth of the newborn
Study: NCT03522025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unicompartmental Knee Arthroplasty (UKA)
Description: Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
Study: NCT04544956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide therapy
Description: Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.
Study: NCT01801072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Details covered in Arm Descriptions.
Study: NCT03878602

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate umbilical cord clamping
Description: Umbilical cord will be clamped immediately after the birth of the newborn
Study: NCT03886363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Described previously
Study: NCT04791007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OB-002
Description: vaginal or rectal administration
Study: NCT02281864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention Bundle
Description: Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group: Quitline
Description: Referral to the Quitline
Study: NCT02029612

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Patch
Description: 10 week supply of nicotine patches given to participants at baseline.

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Patch
Description: 10 week supply of nicotine patches given to participants at baseline.
Study: NCT04199936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Muscle stimulation
Description: Electrical muscle stimulation
Study: NCT03693170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: 300 mg administered orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib 45 mg administered orally twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Standard of care for the 28 first weeks(\*) and then every 2 weeks (\*\*) :~(\*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (\*\*) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward.~Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic.
Study: NCT03130036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
Description: A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
Description: A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
Description: A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study
Study: NCT04021043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-GITR Agonistic Monoclonal Antibody BMS-986156
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-GITR Agonistic Monoclonal Antibody BMS-986156
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-GITR Agonistic Monoclonal Antibody BMS-986156
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT00311662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabersat
Description: Tablet 40mg daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet once daily for 12 weeks
Study: NCT04652232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RV3466F lotion
Description: Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application

Intervention type: OTHER
Group type: OTHER
Intervention: Shampoo
Description: Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shampoo
Description: Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application
Study: NCT04791007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OB-002
Description: vaginal or rectal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: vaginal or rectal administration
Study: NCT01406639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
Study: NCT02494505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 2g/day per os

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01580046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodixanol
Description: 1. coronary angiography, 32gI/100ml, 40～60 ml once injection~2. left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iopromide
Description: coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
Study: NCT01995968

Intervention type: OTHER
Intervention: Antenatal identification of fetal growth restriction
Description: FGR is considered as identified if:~* FGR was mentioned in medical charts~* OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~* OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~* OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~* OR utero-placental Doppler ultrasound indicated for suspicion of growth failure

Intervention type: OTHER
Intervention: Antenatal identification of fetal growth restriction
Description: FGR is considered as identified if:~* FGR was mentioned in medical charts~* OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~* OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~* OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~* OR utero-placental Doppler ultrasound indicated for suspicion of growth failure
Study: NCT01390948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: 75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: 75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: 75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
Study: NCT01588548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1208
Description: Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
Study: NCT02029612

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phone Counseling
Description: Each participant counseled on quitting smoking at baseline.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phone Counseling
Description: Each participant counseled on quitting smoking at baseline.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 3 months, and at 6 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 3 months, and at 6 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breath Test
Description: Breath test performed at 3 month and 6 month visit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breath Test
Description: Breath test performed at 3 month and 6 month visit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Proactive Cell Phone Smoking Cessation Counseling
Description: Participant receives 11 phone calls from study staff over a 6-month period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text Message Smoking Cessation Support
Description: Participants receive text messages for support about quitting smoking over a 6 month period.
Study: NCT05102461

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Florajen Digestion Supplementation
Description: Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
Study: NCT03768973

Intervention type: PROCEDURE
Intervention: Elective cardiac surgery
Description: Both groups will undergo elective cardiac surgery as an intervention.

Intervention type: PROCEDURE
Intervention: Elective cardiac surgery
Description: Both groups will undergo elective cardiac surgery as an intervention.
Study: NCT00884377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium stibogluconate (Pentostam)
Description: intravenous 20 mg/kg/day for 10 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermoMed
Description: ThermoMed heat treatment device, one treatment
Study: NCT02636335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phillips Energy Light HF3319
Description: Exposure to Light administered with Phillips Energy Light HF3319.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phillips Energy Light HF3319
Description: Exposure to Light administered with Phillips Energy Light HF3319.